Search

Your search keyword '"Karino Y"' showing total 248 results

Search Constraints

Start Over You searched for: Author "Karino Y" Remove constraint Author: "Karino Y"
248 results on '"Karino Y"'

Search Results

1. The nylon balloon for xenon loaded liquid scintillator in KamLAND-Zen 800 neutrinoless double-beta decay search experiment

2. The nylon balloon for xenon loaded liquid scintillator in KamLAND-Zen 800 neutrinoless double-beta decay search experiment

3. Erratum: “A Search for Electron Antineutrinos Associated with Gravitational-wave Events GW150914 and GW151226 Using KamLAND” (2016, ApJL, 829, L34)

4. A Search for Electron Antineutrinos Associated with Gravitational-wave Events GW150914 and GW151226 Using KamLAND (vol 829, L34, 2016)

5. Search for electron antineutrinos associated with gravitational wave events GW150914 and GW151226 using KamLAND

6. A SEARCH FOR ELECTRON ANTINEUTRINOS ASSOCIATED WITH GRAVITATIONAL-WAVE EVENTS GW150914 AND GW151226 USING KAMLAND

7. Publisher’s Note: Search for Majorana Neutrinos Near the Inverted Mass Hierarchy Region with KamLAND-Zen [Phys. Rev. Lett. 117, 082503 (2016)]

8. Search for Majorana Neutrinos Near the Inverted Mass Hierarchy Region with KamLAND-Zen

16. Search for Majorana Neutrinos Near the Inverted Mass Hierarchy Region with KamLAND-Zen

17. CERTAIN-1: efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

25. G13 : Ombitasvir/paritaprevir/ritonavir for treatment of HCV genotype 1b in Japanese patients with or without cirrhosis: Results from gift-I

26. Noninvasive Reactor Imaging Using Cosmic-Ray Muons

27. P1216 EFFICACY AND SAFETY OF SIMEPREVIR PLUS PEG-INTERFERON/RIBAVIRIN THERAPY IN PATIENTS WITH HCV GENOTYPE 1 – COMPARISON WITH TELAPREVIR PLUS PEG-INTERFERON/RIBAVIRIN THERAPY AND PEG-INTERFERON/RIBAVIRIN THERAPY

34. Virological response and safety of 24‐week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b

35. 14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN

Catalog

Books, media, physical & digital resources